Factor V Leiden mutation and pregnancy-related venous thromboembolism: What is the exact risk?

Christine Biron-Andreani; Jean-Francois Schved; Jean-Pierre Daures

doi:10.1160/TH06-02-0086

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2006; 96(01): 14-18
DOI: 10.1160/TH06-02-0086

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Factor V Leiden mutation and pregnancy-related venous thromboembolism: What is the exact risk?

Results from a meta-analysis

Christine Biron-Andreani

¹Hopital Saint-Eloi, Laboratoire d’ Hematologie, Montpellier, France

,

Jean-Francois Schved

¹Hopital Saint-Eloi, Laboratoire d’ Hematologie, Montpellier, France

,

Jean-Pierre Daures

²IURC, Laboratoire de Recherche en Biostatistiques et Epidemiologie, Montpellier, France

› Author Affiliations

Abstract

Summary

The magnitude of the association of factor V Leiden mutation with pregnancy-related venous thrombosis remains unclear. Our objective was to undertake a systematic review and a meta-analysis of the literature to estimate precisely the association of factor V Leiden mutation with the risk of first,or recurrent,pregnancy-related venous thromboembolism. Studies published before October 2005 were identified by Medline^®. Using both fixed and random effect models, odds ratios (OR) with accompanying 95% confidential intervals (CI) were calculated for the factor V Leiden mutation and the clinical end-point (Yusuf-Peto adaptation of the Mantel-Haenszel, DerSimonian and Laird method).We identified 13 studies including 7 cohorts and 6 case control studies relating to factor V Leiden and pregnancy-related venous thrombosis.The results from the cohorts showe a pooled OR of 4.46 (95% CI,1.82–10.94;7,879 pooled women), with no evidence of statistical heterogeneity (p=0.36), for the risk of a first venous thromboembolism during pregnancy or the postpartum period associated with the factor V Leiden mutation.Case-control studies revealed a higher risk ( OR 8.6,95% CI, 5.85–12.63; 1,524 pooled women) with significant heterogeneity (p<0.005). Because of insufficient data, an analysis for the risk of recurrence could not be performed. Our findings emphasize the fact that limited data are available on this topic.This meta-analysis provides clinicians with an estimate of the average risk of a first thrombosis occurring during pregnancy in women carrying the factor V Leiden to assist the management of such women.

Keywords

FactorV Leiden mutation - venous thrombosis - pregnancy - meta-analysis

Full Text

References

References
1 Heit JA, Kobbervig CE, James AH. et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005; 143: 697-706.
2 ees DC, Cox M, Clegg JB. World distribution o factor V Leiden. Lancet 1995; 346: 1133-4.
3 Lucotte G, Mercier G. Population genetics of factor Leiden in Europ. Blood Cells Mol Dis 2001; 27: 362-7.
4 Walker I. Guideline: Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114: 512-28.
5 Bates SM, Greer I, Hirsh J. et al. Use of antithrom botic agents during pregnancy. Chest 2004; 126: 627S-44S.
6 Rodger MA, Carrier M, Keely EK. et al. The management of thrombophilia during pregnancy: a Canadian survey. J ObstetGynaecol Can 2002; 24: 946-52.
7 Ministry of Health and Long-term Care. Ontario drug Benefit Formulary. To ronto: Queen’s Printer for Ontario. 2001 pIII. 70-3.
8 DerSimonian R, Laid N. Meta-analysis in clinical trials. Control Clin Trials 1986; 07: 177-88.
9 Yusuf S, Peto R, Lewis J. et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-71.
10 Pabinger I, Nemes L, Rintelen C. et al. Pregnancy-associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor Leiden. Hematol J 2000; 01: 37-41.
11 Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173: 210-3.
12 McColl MD, Ramsay JE, Tait RC. et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 78: 1183-8.
13 Hirsh DR, Mikkola KM, Marks PW. et al. Pulmonary and deep vein thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden. Am Heart J 1996; 131: 1145-8.
14 Hallak M, Senderowicz J, Cassel A. et al. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy. Am J Obstet Gynecol 1997; 176: 889-93.
15 Rose NC, Wang YL, Neubert AG. et al. An evaluation of the factor V Leiden mutation in a cohort of African-American pregnant women. Prenat Diagn 1998; 18: 315-7.
16 Simioni P, Tormene D, Prandoni P. et al. Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study. Blood 2002; 99: 1936-42.
17 Martinelli I, Bucciarelli P, Margaglione M. et al. The risk of venous thromboembolism in family members with mutations in the genes of factor V or pro-thrombin or both. Br J Haematol 2001; 111: 1223-9.
18 Murphy RP, Donoghue C, Nallen RJ. et al. Prospec tive evaluation of the risk conferred by Factor V Leiden and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy. Arterioscler Thromb Va sc Biol 2000; 20: 266-70.
19 Yilmazer M, Kurtay G, Sonmezer M. et al. Factor Leiden and prothrombin 20210 G-A mutations in controls and in patients with thromboembolic events dur ing pregnancy or the puerperium. Arch Gynecol Obstet 2003; 268: 304-8.
20 Ogunyemi D, Cuellar F, Wayne K. et al. Association between inherited thrombophilia, antiphospholipid antibodies and lipoprotein A levels and venous throm boembolism in pregnancy. Am J Perinatol 2003; 20: 17-23.
21 Dizon-Townson DS, Nelson LM, Jang HJ. et al. The incidence of the factor V Leiden mutation in an obstet ric population and its relationship to deep vein throm bosis. Am J Obstet gynecol 1997; 176: 883-6.
22 Bokarewa MI, Bremme K, Blombäck M. Arg506-Gln mutation in factor V and risk of thrombo sis during pregnancy. Br J Haematol 1996; 92: 473-8.
23 Lindqvist PG, Svensson PJ, Marsal K. et al. Activated protein C resistance (FV:Q506) and pregnancy. Thromb Haemost 1999; 81: 532-7.
24 Simioni P, Sanson BJ, Prandoni P. et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81: 198-202.
25 Lensen R, Rosendaal F, Vandenbroucke J. et al. Factor V Leiden: the venous thrombotic risk in thrombo philic families. B J Hematol 2000; 110: 939-45.
26 Tormene D, Simioni P, Prandoni P. et al. Factor Leiden and the risk of venous thromboembolism in pregnant women. Haematol 2001; 86: 1305-9.
27 Brill-Edwards P, Ginsberg JS, Gent M. et al. for the Recurrence Of Clot In This pregnancy (ROCIT) study group. Safety of withholding heparin in women with a previous episode of venous thromboembolism. N Engl J Med 2000; 343: 1439-44.
28 Pabinger I, Grafebhofer H, Kaider A. et al. Risk o pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost 2005; 03: 949-54.
29 Dizon-Townson D, Miller C, Sibai B. et al. The relationship of the factor V Leiden mutation and pregnancy outcomes for mothers and fetus. Obstet Gynecol 2005; 106: 517-24.
30 Grandone E, Margaglione M, Colaizzo D. et al. Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrom bin G20210A, and methylenetetrahydrofolate reduc-tase C677T mutations. Am J Obstet Gynecol 1998; 179: 1324-8.
31 Dilley A, Austin H, El-Jamil M. et al. Genetic factors associated with thrombosis in pregnancy in a United States population. Am J Obst Gynecol 2000; 183: 1271-7.
32 Gerhardt A, Scharf RE, Beckmann MW. et al. Pro-thrombin and factor V mutations in women with a his tory of thrombosis during pregnancy and the puerperi-um. N Engl J Med 2000; 342: 374-80.
33 Martinelli I, De Stefano V, Taioli E. et al. Inherited thrombophilia and first venous thromboembolism dur ing pregnancy and puerperium. Thromb Haemost 2002; 87: 791-5.
34 Meglic L, Stegnar M, Milanez T. et al. Factor Leiden, prothrombin 20210G A, methyltetrahydro-folate reductase 677C T and plasminogen activator in hibitor 4G/5G polymorphism in women with pregnancy-related venousthromboembolism. Eur J ObstGyne-col Reprod Biol 2003; 111: 157-63.
35 Gerhardt A, Scharf RE, Zotz RB. Effect of hemos-tatic risk factors on the individual probability of throm bosis during pregnancy and the puerperium. Thromb Haemost 2003; 90: 77-85.
36 Vandenbroucke JP, Rosendaal FR. Factor V Leiden: a difference in cohort and case-control studies?. Ann Intern Med 2004; 141: p284.
37 Treffers PE, Huidekoper BL, Weenink GH. et al. Epidemiological observations of thromboembolic disease during pregnancy and in the puerperium in 56022 women. Int J Gynecol Obstet 1983; 21: 327-31.
38 Ginsberg JS, Brill-Edwards P, Burrows RF. et al. Ve nous thrombosis during pregnancy: leg and trimester of presentation. Thromb Haemost 1992; 67: 519-20.
39 Clark P, Twaddle S, Walker ID. et al. Cost-effective ness of screening for the factor V Leiden mutation in pregnant women. Lancet 2002; 359: 1919-20.
40 Lindqvist PG, Dahlback B. Reactions to awarenes of activated protein C resistance carriership: a descrip tive study of 270 women. Acta Obstet Gynecol Scand 2003; 82: 467-70.
41 Lindqvist PG, Olofsson P, Dahlback B. Use of selective factor V Leiden screening in pregnancy to identify candidates for anticoagulants. Obstet Gynecol 2002; 100: 332-6.